Jakavi

Active substance

Ruxolitinib

Holder

Novartis Pharma

Status

Running

Indication

Treatment of patients with corticoid-refractory chronic graft vs. host disease after allogeneic stem cell transplantation, who cannot be adequately treated with commercially available alternatives.

Public documents

Approbation

Information for the patient

Informed consent

Last update

04/09/2018

Last updated on 28/09/2022